Written by Agwalogu Bob,
Osteoporosis is often called a “silent disease.” It’s called that because it can progress from one stage to the next without any noticeable symptoms. For older adults, it typically affects; however, the consequences are anything but silent.
For years, the treatment has always followed a fairly predictable path. Patients are encouraged to take calcium and vitamin D, stay active, or may be given an oral bisphosphonate. Those recommendations still work. But advances in healthcare mean that there are now different osteoporosis medications and therapies, which can be tailored to each patient.
This couldn’t come at a better time. As the population ages, the number of fragility fractures also rises. It is actually one of the biggest challenges facing geriatric care today. In fact, a 2025 BMJ study reveals that more than 10 million Americans over age 50 have osteoporosis. Another 43.4 million have low bone mass, and so are at a high risk of it.
This article discusses these leading treatment options, including some of the key factors that should guide your next prescribing decision.
The Growing Clinical Challenge in Older Adults
As we said earlier, osteoporosis is possibly one of the most common problems in geriatric care. Nearly 1 in 5 women over 50 have it, compared with about 1 in 25 men. This number climbs to 27.1% and 5.1% for women and men, respectively, after 65 years. That’s how common it is.
And the clinical stakes can be quite high. A hip fracture, the most devastating complication, comes with a 20% to 25% chance of being fatal within the first year. And it can rob people of their independence, leading to reduced mobility and a significant decline in quality of life, while at it.
Many clinicians have seen it happen: a patient goes from living independently to needing full-time care after a fall. And that’s just the health and personal impact. The economic toll is also staggering, with estimated direct costs in the USA alone reaching around $25.3 billion in 2025. The figures may have changed today, but the overall picture is the same.
Because fracture prevention is really the whole point of treatment, choosing the right therapy for the right patient is one of the most important clinical decisions you’ll have to make in cases like these.
Understanding Modern Osteoporosis Treatment
Modern osteoporosis treatment begins with fracture prevention, which can only happen when you match the right medication to the right patient.
A few years ago, you would simply prescribe the same drug for everyone with low bone density. Not anymore. The preferred approach now is to treat patients based on their fracture risk and potential health benefits.
Doing this involves two major categories:
- Antiresorptive therapies. These are medications that slow bone breakdown by reducing osteoclast activity. Examples include bisphosphonates, Prolia (denosumab), and Reclast (zoledronic acid). These medications work by preserving existing bone and reducing future fracture risk.
- Anabolic therapies. These are bone-building medications. Instead of slowing breakdown, they actively stimulate new bone formation. Examples include Evenity (romosozumab), as well as the teriparatide and abaloparatide families of drugs.
So, how do you choose between antiresorptive therapy and anabolic therapy? Definitely not by considering bone mineral density alone.
You have to evaluate:
- Their fracture risk
- Bone mineral density (BMD)
- History of previous fractures
- Kidney function
- Their ability to adhere to treatment
Let’s not forget the elephant in the room. It is the cost and insurance considerations, which play a huge role in patient adherence.
Take antiresorptive therapies, for example. They’re a great fit for patients with a moderate to high fracture risk, which is why they’re so common among older adults. The problem is that out-of-pocket costs can be really high, and your patients may want to know if the treatments are covered by insurance. The short answer is yes.
Coverage of part of the Prolia cost with Medicare, for example, only happens under Part B when given in a clinic, and under Part D. That’s the rule, and even so, coverage isn’t automatic.
Documented medical necessity is needed to qualify for coverage, according to LIFE143. This means that you, as a doctor, must confirm that the patient has osteoporosis or is at high risk for fractures. You may also have to confirm that oral treatment failed or that the patient showed side effects of oral therapy. This confirmation ensures that Medicare processes the claims without delays or denials.
Comparing Today’s Leading Osteoporosis Medications
The biggest advance in osteoporosis treatment for older adults isn’t just in the arrival of new drugs and therapies.
It’s also the fact that doctors can now tailor treatments to the patients. No more using the same one-size-fits-all approach for someone with mild osteopenia as for an 82-year-old who recently sustained a hip fracture.
In the table below, we’ll summarize some of today’s leading therapies and the key considerations for each.
| Medication | Drug Class | Typical Candidates | Key Advantages | Limitations |
| Prolia (denosumab) | RANKL inhibitor (antiresorptive) | High fracture risk. Intolerant to oral meds. | Twice-yearly shot. No renal dosing. | Must continue treatment. Costly. Long-term data limited. |
| Bisphosphonates (alendronate, risedronate, ibandronate) | Antiresorptive | Moderate fracture risk. First-line option. | Proven safety. Generic. Cheap. Oral. | GI upset. Strict schedule. Poor adherence. Avoid in severe renal disease. |
| Reclast (zoledronic acid) | Antiresorptive | Prefers yearly IV. Can’t tolerate oral. | Yearly infusion. No GI issues. Extensive data. | Flu-like symptoms post-infusion. Needs IV access. Avoid in severe renal disease. |
| Evenity (romosozumab) | Anabolic (dual-action) | Very high fracture risk. | Rapid BMD gains. Builds bone and cuts breakdown. | 12-month limit. Expensive. Assess cardiovascular risk before prescribing. |
Choosing the Right Therapy for Different Patient Profiles
The table above summarizes some of the top medications for osteoporosis today. The question now is: How do you pick?
Simple, really. For a patient with moderate risk, a generic bisphosphonate is usually a solid, cost-effective starting point. But if you have a patient with a prior vertebral or hip fracture, you need to think bigger and potentially start with an anabolic agent. Expert opinion is actually shifting from a “step-up” approach to a “top-down” one for these high-risk individuals. This means initiating therapy with a potent anabolic agent for rapid protection.
But beyond the clinical problem, you also have to think about the person. This means looking at their life expectancy, functional status, and personal goals, not just their T-score. Following this approach, if a patient has renal impairment and can’t take oral bisphosphonates, Prolia becomes an obvious choice.
At the end of the day, the best medication to choose is the one the patient will actually take. Adherence is everything.
Emerging Trends in Osteoporosis Management
Osteoporosis management has moved from vitamin D and calcium to antiresorptive and anabolic therapy, but that doesn’t mean it’s not going to evolve further, because it is.
A good example is the research into sequential therapy, which is gaining steam. In a study published in Osteoporosis International, researchers found that sequencing treatments works. The combination of a bisphosphonate followed by romosozumab boosted spine bone density by over 10%. Romosozumab followed by denosumab (Prolia) also delivered solid gains, with spine BMD increasing by 4%.
Research is also looking at repurposing existing drugs, like with the antihistamine fexofenadine, which is showing great promise in promoting bone formation.
But over and above all of this, we’re moving towards increasingly personalized treatment plans. Dr. Gianina Flocco, a resident at the Cleveland Clinic, said at ENDO 2025, “The results of our study support the need to enhance the individualized initiation of treatment of osteoporosis, even in people who are older than 80.”
FAQs
What’s the main difference between antiresorptive and anabolic osteoporosis drugs?
The difference between antiresorptive drugs and anabolic drugs is in how they work. Anabolic drugs like romosozumab actively stimulate new bone formation, while antiresorptive drugs like Prolia slow down bone breakdown.
Is Prolia safe for patients with kidney disease?
Yes, it is. Prolia doesn’t require renal dose adjustment, which is why it’s common to recommend it for patients with reduced kidney function. However, even though it’s a twice-yearly shot, any benefits disappear rapidly if a dose is missed.
Does Medicare cover osteoporosis medications?
The short answer is yes. However, Medicare coverage is based on how the drug is administered. Part B means that it has to be administered in a clinical setting. Part D means it has to be administered as a prescription. Even then, the patient has to prove that the treatment is a medical necessity.
Final Words
Osteoporosis treatment has come a long way, and you can see just how far in this guide. With the antiresorptive and anabolic therapies now available across multiple drug classes, we now have more opportunities to give older adults a second chance at independence. The key is knowing how to match the right agent and the right sequence to the right patient.
Author Bio
Agwalogu Bob believes great content doesn’t just inform; it resonates and then sticks. For over eight years, he’s been helping agencies across four continents craft just that kind of content: sharp, engaging cut-through-the-noise copy across SaaS, finance, tech, health, and lifestyle.
When he’s not putting pen to paper, you’ll likely find him scouring the internet for funny memes.
Connect with him on LinkedIn or Medium.
Please also review AIHCP’s Certification program and CE courses see if it meets your academic and professional goals. These programs are online and independent study and open to qualified professionals seeking a four year certification